Pfizer, BioNTech report high efficacy of COVID-19 booster shot in study

BERLIN: Pfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.

They said a trial of 10,000 participants aged 16 or older showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent.

The study also found that the booster shot had a favourable safety profile.